Background: Pathological progression from non-alcoholic fatty liver disease (NAFLD) to liver fibrosis (LF) to hepatocellular carcinoma (HCC) is a common dynamic state in many patients. Curcumin, a dietary supplement derived from the turmeric family, is expected to specifically inhibit the development of this progression. However, there is a lack of convincing evidence.Methods: The studies published until June 2023 were searched in PubMed, Web of Science, Embase, and the Cochrane Library databases. The SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) approach was used to evaluate the certainty of evidence. StataSE (version 15.1) and Origin 2021 software programs were used to analyze the critical indicators.Results: Fifty-two studies involving 792 animals were included, and three disease models were reported. Curcumin demonstrates a significant improvement in key indicators across the stages of NAFLD, liver fibrosis, and HCC. We conducted a detailed analysis of common inflammatory markers IL-1β, IL-6, and TNF-α, which traverse the entire disease process. The research results reveal that curcumin effectively hinders disease progression at each stage by suppressing inflammation. Curcumin exerted hepatoprotective effects in the dose range from 100 to 400 mg/kg and treatment duration from 4 to 10 weeks. The mechanistic analysis reveals that curcumin primarily exerts its hepatoprotective effects by modulating multiple signaling pathways, including TLR4/NF-κB, Keap1/Nrf2, Bax/Bcl-2/Caspase 3, and TGF-β/Smad3.Conclusion: In summary, curcumin has shown promising therapeutic effects during the overall progression of NAFLD–LF–HCC. It inhibited the pathological progression by synergistic mechanisms related to multiple pathways, including anti-inflammatory, antioxidant, and apoptosis regulation.

Objective:To investigate the effect of Shenghua decoction combined with misoprostol for treating women with retained products of conception（RPOC） after natural delivery.Methods:210 women with RPOC（excluding placenta accreta） after natural delivery of term pregnancy were randomly divided into three groups（70 cases in each group）.The women in group A were given puerperal health education,the women in group B were given puerperal health education and oral misoprostol treatment,and the women in group C were given Shenghua Decoction combined with misoprostol treatment except to the puerperal health education.The clinical effect of the women in the three groups was observed.Results:There were significant differences in the total effective rate（65.2%,80.3%,and90.8%） and the total curettage rate（28.8%,19.7%,and 10.7%） of the women among group A,group B,and group C（all P＜0.05）.The bleeding time during treatment,the proportion of maximum vaginal bleeding equal to or more than menstrual volume,the sum value of the three diameters of uterus by transvaginal ultrasound in the postpartum42d,the time of menstrual recovery,the number of menstruations before recovery of the regular menstrual cycle,and the rate of menstrual volume reduction of the women in group C,in group B,and in group A had increased gradually.The menstrual days of the women in group C,in group B,and in group A had decreased gradually（all P＜0.05）.The number of menstrual cycles before the recovery of the regular menstrual cycle of the women in group A had significant different from that of the women in group B and that of the women in group C（P＜0.05）,while which of the women in group B had no significant different from that of the women in group C（P＞0.05）.After treatment,the proportion of exclusive breastfeeding of the women in the three groups had increased.The rate of exclusive breastfeeding and the excellent rate of exclusive breastfeeding of the women in group C were significantly higher than those of the women in group A and in group B（P＜0.01）.All the newborns after breast feeding by the women in the three groups during treatment had no abnormal situations,such as diarrhea:blood in the stool,or rash.There was no significant difference in the incidence of adverse reactions of the women between group B and group C（P＞0.05）.Conclusion:Shenghua decoction combined with misoprostol for treating the women with RPOC after natural delivery has better curative effect,which can promote the postpartum recovery of the women,can improve the treatment outcomes,and can promote breast-feeding,with safety,so it is worth of clinical application.

脐带是母胎间气体交换、营养物质供应和代谢产物排出的重要通道.脐带是胎儿循环中最薄弱部分,当脐带受压或出现病变时,可直接或间接引起胎儿血液循环障碍,导致胎儿缺氧、生长受限,甚至死亡[1].脐血管栓塞临床上极少见,但危害极大.因脐血管栓塞研究资料有限,目前国内外涉及的文献以个案报道居多,尚无大样本量的研究,故对于脐血管栓塞的治疗和监护策略尚未形成统一意见,多数病例在产前诊断后选择短期内剖宫产终止妊娠.本文将成都中医药大学附属医院产科收治的1例脐动脉栓塞伴羊水减少的期待治疗病例报道如下,并对近年来国内外有关脐血管栓塞的文献进行回顾,探讨脐血管栓塞的诊断和治疗方案.

Objective To investigate the effect of autologous blood transfusion in the third trimester of pregnancy. Methods From July 2016 to March 2018, 70 pregnant women in the third trimester of pregnancy in a hospital were retrospectively analyzed. The participants were divided into control group and observation group according to different treatment regimens, with 35 cases in each group. The control group received allogeneic blood transfusion, and the observation group received preexisting autologous blood transfusion. The therapeutic effect, coagulation function and incidence of adverse reactions were analyzed and compared between the two groups. Results The good recovery rate of the observation group was significantly higher than that of the control group (P＜0.05), the coagulation function of the observation group was significantly better than that of the control group (P＜0.05), the incidence of adverse reactions in the observation group was significantly lower than that of the control group (P＜0.05). Conclusion Preexisting autologous blood transfusion is effective in the treatment of the third trimester of pregnancy, which can improve the recovery rate, improve the coagulation function and reduce the incidence of adverse reactions.

1 病例资料 患者陈某某,28岁,藏族,因"停经37+1周,阴道流液1+h"于2019年08月03日就诊于成都中医药大学附属医院产科.患者平素月经规律,5/28 d,停经45 d因"先兆流产"于我院妇科住院保胎治疗.

目的:探究球囊引产联合人工破膜及缩宫素在足月妊娠中的引产效果.方法:选择2019年1月至2019年12月于我院接受治疗的82例足月产妇,按照随机数字表法将其均分为研究组与对照组(每组各41例),对照组产妇实施人工破膜,2h后如未见有效宫缩则静脉滴注缩宫素,研究组首先于宫颈处放置COOK球囊,取出球囊后进行人工破膜,30 min后静脉滴注缩宫素,对比两组产妇静滴缩宫素至分娩时间、第1产程、第2产程、总产程时间,对比两组产妇不同时间段分娩率,对比两组产妇自然分娩率、胎儿Apgar评分、产后24 h出血量及副作用情况.结果:(1)研究组产妇缩宫素静滴至分娩时间、第1产程、第2产程、总产程均明显短于对照组(P＜0.05);(2)12 h内研究组分娩率明显高于对照组(P＜0.05);(3)研究组产妇自然分娩率高于对照组(P＜0.05),胎儿Apgar评分差异不明显(P＞0.05),产后24h出血量研究组低于对照组产妇(P＜0.05);(4)两组产妇羊水浑浊、宫缩过强等副作用发生率对比差异不具有统计学意义(P＞0.05).结论:应用球囊引产联合人工破膜及静滴缩宫素的方式,能够显著缩短产妇产程,提高自然分娩率,同时还能够降低分娩后产妇阴道出血量,且安全性较高.

Aim: To explore FBXW7 protein-coding transcript isoform (α, β and γ) expression, their functions and prognostic value in ovarian serous cystadenocarcinoma (OSC). Materials & methods: FBXW7 transcript data were collected from The Cancer Genome Atlas and the Genotype-Tissue Expression project. IOSE, A2780 and SKOV3 cells were used for in vitro and in vivo studies. Results: FBXW7α and FBXW7γ are dominant protein-coding transcripts that were downregulated in OSC. FBXW7γ overexpression reduced the protein expression of c-Myc, Notch1 and Yap1 and suppressed OSC cell growth in vitro and in vivo. FBXW7γ expression was an independent indicator of longer disease-specific survival (HR: 0.588; 95% CI: 0.449-0.770) and progression-free survival (HR: 0.708; 95% CI: 0.562-0.892). Conclusion: FBXW7γ is a tumor-suppressive and might be the only prognosis-related FBXW7 transcript in OSC.